Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
2.890
+0.070 (2.48%)
Jul 21, 2025, 2:16 PM - Market open

Company Description

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.

The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.

It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis, Inc.
Codexis logo
CountryUnited States
Founded2002
IPO DateApr 22, 2010
IndustryBiotechnology
SectorHealthcare
Employees188
CEOStephen Dilly

Contact Details

Address:
200 Penobscot Drive
Redwood City, California 94063
United States
Phone650 421 8100
Websitecodexis.com

Stock Details

Ticker SymbolCDXS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001200375
CUSIP Number192005106
ISIN NumberUS1920051067
Employer ID71-0872999
SIC Code2860

Key Executives

NamePosition
Dr. Stephen George Dilly MBBS, Ph.D.President, Chief Executive Officer and Chairman
Georgia L. ErbezChief Financial Officer
Kevin Norrett M.B.A., M.S.Chief Operating Officer
Dr. Alison Moore Ph.D.Chief Technology Officer and Executive Vice President
Carrie McKimDirector of Investor Relations
Karen Frechou-ArmijoSenior Vice President and Head of Human Resources
Dr. Stefan Lutz Ph.D.Senior Vice President of Research
John SchiffhauerSenior Vice President of Intellectual Property

Latest SEC Filings

DateTypeTitle
Jun 11, 20258-KCurrent Report
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
Apr 24, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2025DEF 14AOther definitive proxy statements
Apr 24, 2025SCHEDULE 13G/AFiling
Apr 9, 20258-KCurrent Report
Mar 31, 20258-KCurrent Report
Feb 27, 202510-KAnnual Report
Feb 27, 20258-KCurrent Report